Rhythm Pharmaceuticals Announces Nature Medicine Publication of Longer-Term Data from Phase 2 Study of Setmelanotide for Treatment ...
Longer-term data from open label study show reductions in hyperphagia and body weight In vitro analyses advance understanding of setmelanotide’s activity at the MC4 receptor, a part of a key pathway regulating energy homeostasis and appetite BOSTON, May …